Neumora Therapeutics (NMRA) awards officer 375K stock options

Rhea-AI Filing Summary

Neumora Therapeutics, Inc. (NMRA) reported that officer Jason Duncan received a grant of stock options for 375,000 shares of common stock. The options have an exercise price of $1.52 per share and expire on August 20, 2036, with all options held as direct ownership.

According to the vesting terms, 25% of the option shares vest on August 20, 2027, the first anniversary of the Vesting Commencement Date, and the remaining shares vest in equal monthly installments over the following three years so that the grant is fully vested on the fourth anniversary.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Duncan Jason

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	375,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 375,000 shares (Direct)

Footnotes (1)

1. F1. 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Key Figures

Options granted: 375,000 shares Exercise price: $1.52 per share Underlying common stock: 375,000 shares +4 more

7 metrics

Options granted 375,000 shares Stock Option (Right to Buy) grant to Jason Duncan on August 20, 2026

Exercise price $1.52 per share Conversion or exercise price of the stock options

Underlying common stock 375,000 shares Shares of common stock underlying the stock option grant

Post-transaction option holdings 375,000 options Total derivative securities held following the reported acquisition

Option expiration date August 20, 2036 Expiration date of the granted stock options

Initial vesting portion 25% of shares Portion of the option that vests on first anniversary of August 20, 2026

Monthly vesting fraction 1/48 of total shares Monthly vesting rate after the first anniversary until fully vested

Key Terms

Stock Option (Right to Buy), Vesting Commencement Date, fully vested and exercisable

3 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Vesting Commencement Date financial

"measured from August 20, 2026 (the "Vesting Commencement Date")"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

fully vested and exercisable financial

"shares subject to the option will be fully vested and exercisable"

FAQ

What equity award did Jason Duncan report on this Form 4 for NMRA?

Jason Duncan reported a grant of stock options for 375,000 shares of Neumora Therapeutics, Inc. common stock, with an exercise price of $1.52 per share and an expiration date of August 20, 2036.

What is the vesting schedule of Jason Duncan’s 375,000 NMRA stock options?

25% of the options vest on August 20, 2027, measured from the August 20, 2026 Vesting Commencement Date. 1/48th of the total shares vest monthly thereafter, so that 100% of the options are fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

What is the exercise price and expiration date of the NMRA options granted to Jason Duncan?

The options granted to Jason Duncan have an exercise price of $1.52 per share and an expiration date of August 20, 2036, covering 375,000 underlying shares of Neumora Therapeutics, Inc. common stock.

How many NMRA option shares does Jason Duncan hold after this reported grant?

Following the reported grant, Jason Duncan holds 375,000 stock options to acquire Neumora Therapeutics, Inc. common stock, all reported as direct ownership in this Form 4 filing.

Is the Jason Duncan NMRA option grant reported as a purchase or an award?

The filing characterizes the transaction as a grant, award, or other acquisition of derivative securities under transaction code A, rather than an open-market purchase, with 375,000 stock options awarded at an exercise price of $1.52 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/21/2026 - 07:09 PM Accepted by SEC EDGAR 08/21/2026 - 07:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Duncan Jason

(Last) (First) (Middle)

C/O NEUMORA THERAPEUTICS, INC.

260 ARSENAL PLACE, SUITE 1

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Neumora Therapeutics, Inc. [ NMRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.52	08/20/2026		A		375,000		(1)	08/20/2036	Common Stock	375,000	$0	375,000	D

Explanation of Responses:

1. 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Remarks:

Title: Chief Legal and Administrative Officer

	/s/ Michael Milligan, as Attorney-in-Fact for Jason Duncan	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)